ClinicalTrials.gg
RecruitingNCT07268248PAGE1Updated Nov 18, 2026

1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study

An interventional study of IV glucocorticoid and antihistamine and IV glucocorticoid and antihistamine (standard of care) in Allergic Reaction to Contrast Media, Hypersensitivity Reaction and Computed Tomography, sponsored by Paul Peng, MD PhD MSCR. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Paul Peng, MD PhD MSCR · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 18, 2026Now RecruitingStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 302 studies in Hypersensitivity with a site in United States — 34 open to participants now, 42 under way, 1 of them phase 3. Hypersensitivity · United States.

Planned enrollment
22nd of 221
540 · median 60
Started
2026
with 11 others
No phase
69 of 302
8 open now
Primary completion
2028-12
later than 31 of 40 live
Registered
291st of 302
by date

Among the 302 studies in Hypersensitivity with a site in United States, this one is the 22nd largest by planned enrollment of the 221 interventional ones that give a count, is one of 12 that started in 2026, is one of 69 with no phase, reaches primary completion later than 31 of the 40 other live ones, and was the 291st registered.

Hypersensitivity

1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

34 of the 302 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 302 studies in Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

1-hour Premedication for Allergy Goal in Emergency: PAGE-1 is a prospective, parallel, two-arm, non-inferiority, randomized controlled trial evaluating the safety of a 1-hour (intervention) versus a 4-hour (standard regimen) intravenous (IV) premedication protocol in adult patients in the Emergency Department (ED) with a documented iodinated contrast allergy and requiring computed tomography (CT) imaging for a high-risk indication.

Read the detailed description

Allergic or hypersensitivity reactions to iodinated contrast media are rare, estimated to occur in 0.3% to 1.4% of cases, but have decreased significantly after the switch from high-osmolar to low-osmolar contrast. Most reactions are mild, and breakthrough reactions occur regardless of the timing of premedication. IV premedication is recommended, but there is no level I evidence for its basis in the ED.

This study addresses the sparse evidence that underpins the ubiquitous multi-hour premedication protocols in EDs nationwide. It specifically challenges the existing paradigm of 4-5 hours of IV premedication, which has remarkably never been prospectively validated.

03

Conditions studied

  • Allergic Reaction to Contrast Media
  • Hypersensitivity Reaction
  • Computed Tomography
  • Premedication

Browse trials for

Keywords

  • Iodinated Contrast Reaction
  • Contrast-enhanced CT
  • Glucocorticoid prophylaxis
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥ 21 years old)
  2. Documented iodinated contrast allergy in the electronic health record
  3. CT with iodinated contrast ordered for a high-risk indication, † defined as post-arrest, concern for aortic dissection, ischemia, occlusion, obstruction, or other life-threatening conditions requiring timely diagnosis
  4. Willing and able to give consent

Exclusion criteria

Exclusion Criteria:

  1. Previous enrollment in this study
  2. Pregnancy
  3. Seafood or iodine allergy, alone
  4. Gadolinium allergy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    1-hour Premedication Protocol

    IV glucocorticoid and antihistamine 1 hour before contrast

    Other: IV glucocorticoid and antihistamine

  • Active comparator
    4-hour Premedication Protocol

    IV glucocorticoid 4 hours before contrast and IV antihistamine 1 hour before contrast

    Other: IV glucocorticoid and antihistamine (standard of care)

Interventions

  • OtherIV glucocorticoid and antihistamine

    Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately plus diphenhydramine 25 mg IV 1 hour before contrast medium administration for CT imaging

  • OtherIV glucocorticoid and antihistamine (standard of care)

    Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately 4 hours before contrast medium administration, plus diphenhydramine 25 mg IV 1 hour before contrast for CT imaging

06

What researchers measure

Primary outcomes

  1. Difference in proportion of Acute Contrast Reaction

    Measurement of any contrast reaction after contrast administration

    Time frame: 30 minutes

  2. Proportion of patients eligible for intervention

    Ratio of those eligible to screened

    Time frame: Before randomization

Secondary outcomes

  1. Proportion randomized to intervention and control

    Ratio of patients randomized to intervention and control arms, and who complete the protocol as specified

    Time frame: Within 30 minutes after completion of CT imaging

  2. Adverse events after intervention

    Proportion of patients who required intramuscular epinephrine, noninvasive ventilation, or intubation

    Time frame: Within 30 minutes after assessment of primary outcome

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Davenport MS, Cohan RH. The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients. Radiol Clin North Am. 2017 Mar;55(2):413-421. doi: 10.1016/j.rcl.2016.10.012. PubMed 28126223 ↗
  • Greenberger PA, Halwig JM, Patterson R, Wallemark CB. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1986 Apr;77(4):630-4. doi: 10.1016/0091-6749(86)90357-x. PubMed 3958391 ↗
  • Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH, Stolberg HO. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987 Oct 1;317(14):845-9. doi: 10.1056/NEJM198710013171401. PubMed 3627208 ↗
  • Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990 Jun;175(3):621-8. doi: 10.1148/radiology.175.3.2343107. PubMed 2343107 ↗
  • Amiri E. Optimizing Premedication Strategies for Iodinated Contrast Media in CT scans: A Literature Review. J Med Imaging Radiat Sci. 2025 Jan;56(1):101782. doi: 10.1016/j.jmir.2024.101782. Epub 2024 Nov 20. PubMed 39571411 ↗
  • Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol. 2001 Jun;176(6):1389-92. doi: 10.2214/ajr.176.6.1761389. PubMed 11373198 ↗
  • Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. AJR Am J Roentgenol. 2015 Jul;205(1):77-84. doi: 10.2214/AJR.14.13810. PubMed 26102383 ↗
  • Mervak BM, Cohan RH, Ellis JH, Khalatbari S, Davenport MS. Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen. Radiology. 2017 Nov;285(2):425-433. doi: 10.1148/radiol.2017170107. Epub 2017 Jul 26. PubMed 28745940 ↗
  • Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol. 2008 Aug;191(2):409-15. doi: 10.2214/AJR.07.3421. PubMed 18647910 ↗
  • Goldfarb JW. National trends in contrast media enhanced and unenhanced computed tomography use. Clin Imaging. 2023 Jan;93:103-105. doi: 10.1016/j.clinimag.2022.11.009. Epub 2022 Nov 17. No abstract available. PubMed 36427426 ↗
  • Berlyand Y, Fraga JA, Succi MD, Yun BJ, Lee AH, Baugh JJ, Whitehead D, Raja AS, Prabhakar AM. Impact of iodinated contrast allergies on emergency department operations. Am J Emerg Med. 2022 Nov;61:127-130. doi: 10.1016/j.ajem.2022.08.052. Epub 2022 Sep 5. PubMed 36096014 ↗
  • Wang C, Ramsey A, Lang D, Maria Copaescu A, Krishnan P, Kuruvilla M, Mervak B, Newhouse J, Sumkin A, Saff R. Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology. Radiology. 2025 May;315(2):e240100. doi: 10.1148/radiol.240100. PubMed 40326871 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study protocol and statistical plan

Supporting information: Study protocol, Statistical analysis plan

Time frame: Available after start date and 1 year after end of study

Access criteria: Study coordinators and key personnel

Data sharing details ↗ · redcap.rutgers.edu

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 151 non-industry interventional studies with no phase under Hypersensitivity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 43. This study's planned 27 months is above that.

Counting every sponsor, half of 175 studies reached it within 20 months; a quarter within 5 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2026 → Sep 2026, primary completion Dec 2027 → Dec 2028 and completion Jun 2028 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 5, 2025
StartActual
Sep 1, 2026was Jun 2026
Primary completionEst.
Dec 2028was Dec 2027
CompletionEst.
Jan 2029was Jun 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in United States
Show site
  • Rutgers, Robert Wood Johnson Hospital · New Brunswick, United States
Nov 18, 2026
Start date
Jun 2026→Sep 1, 2026 (actual)
Nov 18, 2026
Primary completion
Dec 2027→Dec 2028
Nov 18, 2026
Study completion
Jun 2028→Jan 2029
Nov 18, 2026
Documents
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Documents Informed consent form ↗ posted
    1 site added — first site in United States
    Show site
    • Rutgers, Robert Wood Johnson Hospital · New Brunswick, United States
    Start date Jun 2026→Sep 1, 2026 (now actual)
    Primary completion Dec 2027→Dec 2028
    Study completion Jun 2028→Jan 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07268248
Lead sponsor
Paul Peng, MD PhD MSCR
Responsible party
Paul Peng, MD PhD MSCR (Assistant Professor, Rutgers, The State University of New Jersey) — Sponsor-investigator
First posted
Dec 5, 2025
Start date
Sep 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Chirag N Shah, MD
Contact
shahcn@rwjms.rutgers.edu
732-235-8717
Paul Peng
principal investigator · Rutgers Robert Wood Johnson Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion